Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Elisabetta Pfanner"'
Autor:
Elisa Sensi, Elisabetta Pfanner, Lisa Salvatore, Francesca Bergamo, Carlotta Antoniotti, Marta Schirripa, Cristiana Lupi, Fotios Loupakis, Vittorina Zagonel, Isa Brunetti, Chiara Cremolini, Alfredo Falcone, Angela Michelucci, Sara Lonardi, Paolo Simi, Gianluca Masi, Gabriella Fontanini
Publikováno v:
European Journal of Cancer. 50:57-63
Background BRAF V600E mutation plays a negative prognostic role in metastatic colorectal cancer (mCRC), leading to a median Progression Free Survival (PFS) of 4–6 months with first-line conventional treatments. Our group recently reported in a retr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd18b49f0226f04f033522bb0789769
https://doi.org/10.1016/j.ejca.2013.08.024
https://doi.org/10.1016/j.ejca.2013.08.024
Autor:
Mario Spione, Laura Delliponti, Elisabetta Pfanner, Beatrice Borelli, Lisa Salvatore, Gianluca Masi, Elena Ongaro, Roberto Moretto, Gemma Zucchelli, Federica Marmorino, Carlotta Antoniotti, Francesca Vannini, Isa Brunetti, Chiara Cremolini, Alfredo Falcone, Daniele Rossini, Camilla Colombo
Publikováno v:
Colorectal Cancer. 7:CRC01
Aim: RECOURSE trial has shown a benefit for trifluridine/tipiracil (also known as TAS-102) over placebo in chemorefractory metastatic colorectal cancer (mCRC) patients. We evaluated efficacy and safety of patients treated with trifluridine/tipiracil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25779d6d9d2b5c907fdf2789e202f399
https://doi.org/10.2217/crc-2017-0023
https://doi.org/10.2217/crc-2017-0023
Autor:
Chiara Cremolini, Laura Delliponti, Alfredo Falcone, Camilla Colombo, Carlotta Antoniotti, Francesca Vannini, Marzia Pennati, Gianluca Masi, Daniele Rossini, Isa Brunetti, Nadia Zaffaroni, Beatrice Borelli, Alessandra Saettini, Serenella Gini, Federica Marmorino, Gemma Zucchelli, Filippo Pietrantonio, Roberto Moretto, Elisabetta Pfanner
Publikováno v:
Annals of Oncology. 28:vi4
675 Background: Regorafenib is a treatment option for refractory mCRC pts. Considering its limited clinical benefit and the palliative setting, patients’ selection is essential to optimize the cost-effectiveness ratio. We aimed to describe the modu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8497a1e9ca1edc8748419d9d6ea4a463
https://doi.org/10.1093/annonc/mdx422.004
https://doi.org/10.1093/annonc/mdx422.004
Autor:
Gino Malvaldi, Michele Andreuccetti, M. Del Tacca, Andrea Antonuzzo, Alfredo Falcone, Romano Danesi, Isa Brunetti, Pierfranco Conte, Elisabetta Pfanner, Monica Lencioni, Giacomo Allegrini
Publikováno v:
Annals of Oncology. 8:539-545
Summary Background Experimental studies have demonstrated that 5-fluorouracil (5-FU) enhances zidovudine (AZT)-induced DNA strand breaks and cytotoxicity. Phase I studies have demonstrated that the maximum tolerable dose (MTD) of AZT is 8000 mg/sqm w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5116d0cc62e6b6d6396531abf02e73f1
https://doi.org/10.1023/a:1008249803523
https://doi.org/10.1023/a:1008249803523
Autor:
Barbara Salvadori, A. Aontana, E. Molinaro, Andrea Michelotti, C. De Angelis, A. Falcone, I. Bertolini, E. Landucci, Elisabetta Pfanner, Lucrezia Diodati, I. Ferrarini, P. Ferrari, I. Montagnani
Publikováno v:
Annals of Oncology. 27:iv72
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68fb36664cf888dfbdc31364122f9d3f
https://doi.org/10.1093/annonc/mdw337.41
https://doi.org/10.1093/annonc/mdw337.41
Autor:
E. Landucci, M. Lo Russo, C. De Angelis, I. Bertolini, Flaviano Di Paola, Manuela Roncella, Elisabetta Pfanner, Lucrezia Diodati, I. Ferrarini, Andrea Michelotti, A. Falcone, Annalisa Fontana, Barbara Salvadori, I. Montagnani
Publikováno v:
Annals of Oncology. 27:iv74
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e9f06658a379101ed9cc4e5f5f5d78b
https://doi.org/10.1093/annonc/mdw337.51
https://doi.org/10.1093/annonc/mdw337.51
Autor:
Andrea Michelotti, Matteo Ghilli, Manuela Roncella, Barbara Salvadori, C. De Angelis, M. Lo Russo, I. Bertolini, E. Rossetti, Elisabetta Pfanner, I. Ferrarini, A. Falcone, Annalisa Fontana, L. Fustaino, Lucrezia Diodati, E. Landucci, P. Ferrari, I. Montagnani
Publikováno v:
Annals of Oncology. 27:iv72
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37ed0c69a3ccd10f5e5c05d38177df77
https://doi.org/10.1093/annonc/mdw337.43
https://doi.org/10.1093/annonc/mdw337.43
Autor:
M. Del Tacca, Isa Brunetti, Pierfranco Conte, C. Cianci, Elisabetta Pfanner, Romano Danesi, Alfredo Falcone
Publikováno v:
Cancer. 75:440-443
Background. The results of conventional chemotherapy in metastatic colorectal cancer are discouraging, making it a logical target for new treatment approaches a necessary consideration. Suramin is a polysulfonated naphthylurea that binds to several c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5653870a0e7cf1b65b62c4adfbb1f6b3
https://doi.org/10.1002/1097-0142(19950115)75:2<440::aid-cncr2820750205>3.0.co
https://doi.org/10.1002/1097-0142(19950115)75:2<440::aid-cncr2820750205>3.0.co
Autor:
Lorenzo Fornaro, Andrea Antonuzzo, Guido Bocci, Enrico Vasile, Alfredo Falcone, Silvana Chiara, Fotios Loupakis, Elisabetta Pfanner, M. Del Tacca, S. Bursi, Gianluca Masi, A. Di Paolo
Publikováno v:
Cancer chemotherapy and pharmacology. 63(5)
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48be7cf0e3e7b846c7e9a1dfeb8acccf
https://pubmed.ncbi.nlm.nih.gov/18839174
https://pubmed.ncbi.nlm.nih.gov/18839174
Autor:
Gianluca Masi, Andrea Antonuzzo, Fotios Loupakis, S. Bursi, Giacomo Giulio Baldi, Iacopo Petrini, C. Sonaglio, Alfredo Falcone, M. T. Barletta, Elisabetta Pfanner
Publikováno v:
Università di Pisa-IRIS
4096 Background: FOLFOXIRI demonstrated manageable toxicities and improved activity and efficacy compared to FOLFIRI in MCRC in a phase III trial by the G.O.N.O. group. Oral C has demonstrated similar efficacy to 5-FU and might substitute 5-FU in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227a727d9e77348ca25ecf3c47a0c13a
http://hdl.handle.net/11568/117051
http://hdl.handle.net/11568/117051
